NVCR
Income statement / Annual
Last year (2023), NovoCure Limited's total revenue was $509.34 M,
a decrease of 5.30% from the previous year.
In 2023, NovoCure Limited's net income was -$207.04 M.
See NovoCure Limited’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$509.34 M
|
$537.84 M
|
$535.03 M
|
$494.37 M
|
$351.32 M
|
$248.07 M
|
$177.03 M
|
$82.89 M
|
$33.09 M
|
$15.49 M
|
| Cost of Revenue |
$128.28 M |
$114.87 M |
$114.88 M |
$106.50 M |
$88.61 M |
$80.05 M |
$55.61 M |
$46.28 M |
$20.61 M |
$10.04 M |
| Gross Profit |
$381.06 M |
$422.97 M |
$420.15 M |
$387.87 M |
$262.71 M |
$168.02 M |
$121.42 M |
$36.61 M |
$12.48 M |
$5.45 M |
| Gross Profit Ratio |
0.75 |
0.79 |
0.79 |
0.78 |
0.75 |
0.68 |
0.69 |
0.44 |
0.38 |
0.35 |
| Research and Development
Expenses |
$223.06 M
|
$206.09 M
|
$201.30 M
|
$132.01 M
|
$79.00 M
|
$50.57 M
|
$38.10 M
|
$41.47 M
|
$43.75 M
|
$40.38 M
|
| General & Administrative
Expenses |
$164.06 M
|
$132.75 M
|
$126.13 M
|
$107.44 M
|
$87.95 M
|
$73.46 M
|
$59.11 M
|
$51.01 M
|
$33.86 M
|
$24.05 M
|
| Selling & Marketing
Expenses |
$226.81 M
|
$173.66 M
|
$137.06 M
|
$118.02 M
|
$96.68 M
|
$77.66 M
|
$63.53 M
|
$59.45 M
|
$38.86 M
|
$21.18 M
|
| Selling, General &
Administrative Expenses |
$390.87 M
|
$306.41 M
|
$263.18 M
|
$225.45 M
|
$184.62 M
|
$151.12 M
|
$122.64 M
|
$110.46 M
|
$72.73 M
|
$45.23 M
|
| Other Expenses |
$4.64 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$613.93 M |
$512.50 M |
$464.49 M |
$357.46 M |
$263.63 M |
$201.69 M |
$160.75 M |
$151.92 M |
$116.47 M |
$85.61 M |
| Cost And Expenses |
$742.21 M |
$627.36 M |
$579.36 M |
$463.97 M |
$352.23 M |
$281.74 M |
$216.35 M |
$198.21 M |
$137.08 M |
$95.65 M |
| Interest Income |
$19.64 M |
$10.96 M |
$791,000.00 |
$1.79 M |
$4.40 M |
$2.65 M |
$1.12 M |
$659,000.00 |
$84,000.00 |
$143,000.00 |
| Interest Expense |
$3.32 M |
$3.33 M |
$3.44 M |
$13.15 M |
$13.72 M |
$13.49 M |
$10.26 M |
$5.94 M |
$2.37 M |
$41,000.00 |
| Depreciation &
Amortization |
$10.97 M
|
$10.62 M
|
$10.25 M
|
$9.15 M
|
$8.39 M
|
$9.01 M
|
$7.68 M
|
$5.65 M
|
$3.15 M
|
$1.96 M
|
| EBITDA |
-$176.66 M
|
-$89.52 M
|
-$44.33 M
|
$30.40 M
|
-$914,000.00
|
-$33.67 M
|
-$39.33 M
|
-$115.32 M
|
-$104.00 M
|
-$78.19 M
|
| EBITDA Ratio |
-0.35 |
-0.17 |
-0.08 |
0.06 |
-0 |
-0.14 |
-0.22 |
-1.39 |
-3.14 |
-5.05 |
| Operating Income Ratio
|
-0.46
|
-0.17
|
-0.08
|
0.04
|
-0
|
-0.14
|
-0.22
|
-1.39
|
-3.14
|
-5.17
|
| Total Other
Income/Expenses Net |
-$797,000.00
|
$7.68 M
|
-$7.74 M
|
-$3.15 M
|
-$7.91 M
|
-$398,000.00
|
$549,000.00
|
-$396,000.00
|
-$356,000.00
|
-$104,000.00
|
| Income Before Tax |
-$191.74 M |
-$81.85 M |
-$52.08 M |
$18.10 M |
-$8.82 M |
-$45.94 M |
-$48.50 M |
-$121.46 M |
-$107.15 M |
-$80.30 M |
| Income Before Tax Ratio
|
-0.38
|
-0.15
|
-0.1
|
0.04
|
-0.03
|
-0.19
|
-0.27
|
-1.47
|
-3.24
|
-5.18
|
| Income Tax Expense |
$15.30 M |
$10.69 M |
$6.28 M |
-$1.71 M |
-$1.59 M |
$17.62 M |
$13.17 M |
$10.38 M |
$4.43 M |
$382,000.00 |
| Net Income |
-$207.04 M |
-$92.53 M |
-$58.35 M |
$19.81 M |
-$7.23 M |
-$63.56 M |
-$61.66 M |
-$131.85 M |
-$111.58 M |
-$80.68 M |
| Net Income Ratio |
-0.41 |
-0.17 |
-0.11 |
0.04 |
-0.02 |
-0.26 |
-0.35 |
-1.59 |
-3.37 |
-5.21 |
| EPS |
-1.95 |
-0.88 |
-0.56 |
0.2 |
-0.0744 |
-0.69 |
-0.7 |
-1.54 |
-3.67 |
-1.12 |
| EPS Diluted |
-1.95 |
-0.88 |
-0.56 |
0.18 |
-0.0744 |
-0.69 |
-0.7 |
-1.54 |
-3.67 |
-1.12 |
| Weighted Average Shares
Out |
$106.39 M
|
$104.66 M
|
$103.43 M
|
$100.93 M
|
$97.24 M
|
$91.83 M
|
$88.55 M
|
$85.56 M
|
$30.40 M
|
$72.14 M
|
| Weighted Average Shares
Out Diluted |
$106.39 M
|
$104.66 M
|
$103.43 M
|
$108.88 M
|
$97.24 M
|
$91.83 M
|
$88.55 M
|
$85.56 M
|
$30.40 M
|
$72.14 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
